Previous 10 | Next 10 |
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has entered into ...
Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today an...
2023-09-05 11:29:20 ET More on Akari Therapeutics Seeking Alpha’s Quant Rating on Akari Therapeutics Financial information for Akari Therapeutics For further details see: Akari Therapeutics regains compliance with Nasdaq minimum bid price requirement
NEW YORK and LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the company has received written notification from Nasdaq that it has regained ...
2023-08-18 10:19:27 ET Gainers: Aditxt ( ADTX ) +50% . AlloVir ( ALVR ) +18% . Agenus ( AGEN ) +7% . Veru ( VERU ) +7% . Akari Therapeutics ( AKTX ) +6% . Losers: Evelo Biosciences ( EVLO ) -37% . Diffusi...
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced the establishment of a Boston Seaport area office that is the company’s U...
2023-08-17 10:07:42 ET Gainers: CervoMed ( CRVO ) +86% . Tivic Health Systems ( TIVC ) +34% . Jupiter Wellness ( JUPW ) +11% . NEXGEL ( NXGL ) +9% . Kamada ( KMDA ) +8% . Losers: Check-Cap ( CHEK ) -23% . ...
2023-08-15 08:41:43 ET Akari Therapeutics ( NASDAQ: AKTX ) said on Tuesday that it plans to change the ratio of its American Depositary Shares to ordinary shares from one ADS representing one hundred ordinary shares to a new ratio of one ADS representing two thousand...
NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari will change the ratio of its American Depositary Shares (ADSs) to or...
NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of Beth-Anne Lang, as Senior Vice President, Regulatory Affairs...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...